ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: 1616 • ACR Convergence 2020

    Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature

    Heather Bannerman1, Karen Beattie1, Avanti Patel2, Milica Tanic2, Michelle Batthish3 and Mark Matsos2, 1McMaster University, Hamilton, ON, Canada, 2McMaster University, Hamilton, Canada, 3McMaster Children's Hospital, Hamilton, ON, Canada

    Background/Purpose: In young patients with rheumatologic disease, transition from pediatric to adult care is a complex process. Poor transitional care leads to health deterioration, loss…
  • Abstract Number: 0711 • ACR Convergence 2020

    Alternative Dosing of Biologic Therapies Is Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Colleen Correll1, Peter Shrader2, Anne Dennos3, Thomas Phillips2, Natalie Shiff4, Ruud Verstegen5 and Timothy Beukelman6, 1University of Minnesota, Minneapolis, MN, 2Duke University, Durham, 3Duke University, Durham, NC, 4Florida, Gainesville, FL, 5The Hospital for Sick Children, Toronto, ON, Canada, 6University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Biologic agents are integral to the treatment of juvenile idiopathic arthritis (JIA) and associated uveitis. Pediatric rheumatologists may increase the dosage of biologics beyond…
  • Abstract Number: 0730 • ACR Convergence 2020

    To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?

    Maria Teran1, Alina Lucica Boteanu2, Carlos Guillen1, Cristina Pijoan1, Jose Quinones1, Veronica Garcia3, Ivan Del Bosque-Granero3, Laura Calvo-Sanz4 and Mónica Vázquez4, 1Hospital Ramon y Cajal, Madrid, Madrid, Spain, 2PRINTO, Istituto Giannina Gaslini, Genova, Italy, 3Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 4Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain

    Background/Purpose: To determine the association between the occurrence of uveitis flares in patients with Juvenile Idiopathic Arthritis (JIA) and the de-intensification of immunosuppressive treatment.Methods: We…
  • Abstract Number: 1617 • ACR Convergence 2020

    New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network

    Julia Harris1, Esi Morgan2, Sheetal Vora3, Mileka Gilbert4, Cagri Yildirim-Toruner5, Nancy Griffin6, Kerry Ferraro7, Stephanie Loos6, Tingting Qiu8, Anne Paul9, Jon Burnham10, Michelle Batthish11, Beth Gottlieb12, Danielle Bullock13, Melissa Hazen14, Ronald Laxer15, Tzielan Lee16, Melissa Mannion17, Judyann Olson18, Nancy Pan19, Michael Shishov20, Charles Spencer21, Jennifer E Weiss22 and C. April Bingham23, 1Children's Mercy Kansas City, Overland Park, KS, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Atrium Health Levine Children's Hospital, Charlotte, NC, 4Medical University of South Carolina, Charleston, SC, 5Nationwide Children's Hospital, Houston, TX, 6Cincinnati Children's Hospital Medical Center, Cincinnati, 7Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, 8Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, 10Children's Hospital of Philadelphia, Philadelphia, PA, 11McMaster Children's Hospital, Hamilton, ON, Canada, 12Cohen Children's Medical Center, Lake Success, NY, 13University of Minnesota, Minneapolis, MN, 14Boston Children's Hospital, Boston, MA, 15The Hospital for Sick Children, Toronto, ON, Canada, 16Stanford University School of Medicine, Palo Alto, CA, 17University of Alabama at Birmingham, Birmingham, AL, 18Medical College of Wisconsin, Milwaukee, WI, 19Hospital for Special Surgery, New York, NY, 20Phoenix Children's Hospital, Phoenix, AZ, 21University of Mississippi, Jackson, MS, 22PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 23Penn State Children's Hospital, Allentown, PA

    Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning network to support pediatric rheumatology centers in improving care delivery and patient…
  • Abstract Number: 0712 • ACR Convergence 2020

    Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis

    Ilaria Maccora1, Gabriele Simonini2, Alessandra Bettiol3, Ilaria Pagnini4, Niccolò Lombardi5, Valerio Maniscalco6, Giada Crescioli5, Edoardo Marrani7, Roberto Bonaiuti5, Maria Vincenza Mastrolia8, Claudia Ravaldi9 and Alfredo Vannacci5, 1Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, 2Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy, 32. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy, Florence, 41. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy, florence, Italy, 52. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Florence, Italy, 61. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy., florence, Italy, 7University of Florence, Firenze, Italy, 8Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, 93. Department of Health Sciences, University of Florence, Florence, Italy., Florence, Italy

    Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…
  • Abstract Number: 0731 • ACR Convergence 2020

    Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U

    Jackeline Rodriguez-Smith1, Virginia Miraldi Utz2, Amy Cassedy1, Sherry Thornton1, Grant Schulert3, Alyssa Sproles4, Najima Mwase1, Theresa Hennard1, Mekibib Altaye2, Alexei Grom1 and Sheila Angeles-Han1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, 3PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital, Cincinnati

    Background/Purpose: The pathogenesis of pediatric uveitis remains unclear. Studies of biomarkers using aqueous humor (AqH) identified S100 proteins, cytokines, and chemokines as potential biomarkers of…
  • Abstract Number: 1634 • ACR Convergence 2020

    Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?

    Therese Posas-Mendoza1, Cara McLeod1, William Davis2 and Robert Quinet2, 1Ochsner Medical Center, New Orleans, LA, 2Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA

    Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH…
  • Abstract Number: 0713 • ACR Convergence 2020

    Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry

    Daniel J Lovell1, Hermine Brunner2, Nikolay Tzaribachev3, Esi Morgan2, Gabriele Simonini4, Thomas Griffin5, Ekaterina Alexeeva6, John Bohnsack7, Andrew Zeft8, Gerd Horneff9, Richard Vehe10, Valda Stanevicha11, Stacey Tarvin12, Maria Trachana13, Adam Huber14, Ilonka Orban15, Jason Dare16, Ivan Foeldvari17, Pierre Quartier18, Alyssa Dominique19, Tzuyung Douglas Kou19, Robert Wong19, Alberto Martini20 and Nicolino Ruperto20, 1PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 4Anna Meyer Children's Hospital, Firenze, Italy, 5Levine Children's Hospital, Charlotte, NC, 6Scientific Center of Children’s Health of RAMS, Moscow, Russia, 7University of Utah and Primary Children's Hospital, Cincinnati, OH, 8Cleveland Clinic, Cleveland, OH, 9Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 10University of Minnesota, Minneapolis, MN, 11Riga Stradins University, Riga, Latvia, 12Riley Children’s Health, Indianapolis, IN, 13Aristotle University of Thessaloniki, Thessaloníki, Greece, 14Dalhousie University, Halifax, NS, Canada, 15National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 16University of Arkansas for Medical Sciences, Little Rock, AR, 17Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, 18Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 19Bristol-Myers Squibb Company, Princeton, NJ, 20PRINTO, Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients with JIA has been demonstrated…
  • Abstract Number: 0733 • ACR Convergence 2020

    Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis

    Ivan Foeldvari1, Jens Klotsche2, Sheila Angeles-Han3, Jordi Anton4, Gabriele Simonini5, Nadine Groesch2 and Jean Baer6, 1Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, 2German Rheumatism Research Center, Berlin, Germany, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Sant Joan de Déu Hospital, Madrid, Spain, 5Anna Meyer Children's Hospital, Firenze, Italy, 6Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany

    Background/Purpose: Juvenile idiopathic arthritis associated uveitis (JIAU) is the most common extra-articular manifestation of JIA, and occurs in approximately 10% of affected children.  Although there…
  • Abstract Number: 1682 • ACR Convergence 2020

    Goal-Setting Improves Transition Readiness in Adolescents with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus

    Teresa Semalulu1, Karen Beattie1, Jeanine McColl1, Arzoo Alam2, Steffy Thomas2, Julie Herrington3, Jan Willem Gorter2, Tania Cellucci2, Stephanie Garner1, Liane Heale2, Mark Matsos1 and Michelle Batthish4, 1McMaster University, Hamilton, ON, Canada, 2McMaster University, Hamilton, Canada, 3ACPAC - University of Toronto, Hamilton, ON, Canada, 4McMaster Children's Hospital, Hamilton, ON, Canada

    Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased morbidity, mortality and loss to follow-up. This is largely due to a…
  • Abstract Number: 0714 • ACR Convergence 2020

    Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry

    Daniel J Lovell1, Nikolay Tzaribachev2, Esi Morgan3, Gabriele Simonini4, Thomas Griffin5, Ekaterina Alexeeva6, John Bohnsack7, Andrew Zeft8, Gerd Horneff9, Richard Vehe10, Valda Stanevicha11, Stacey Tarvin12, Maria Trachana13, Adam Huber14, Daniel Kietz15, Ilonka Orban16, Jason Dare17, Ivan Foeldvari18, Pierre Quartier19, Alyssa Dominique20, Tzuyung Douglas Kou20, Robert Wong20, Alberto Martini21, Hermine Brunner3 and Nicolino Ruperto22, 1PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Anna Meyer Children's Hospital, Firenze, Italy, 5Levine Children's Hospital, Charlotte, NC, 6Scientific Center of Children’s Health of RAMS, Moscow, Russia, 7University of Utah and Primary Children's Hospital, Cincinnati, OH, 8Cleveland Clinic, Cleveland, OH, 9Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 10University of Minnesota, Minneapolis, MN, 11Riga Stradins University, Riga, Latvia, 12Riley Children’s Health, Indianapolis, IN, 13Aristotle University of Thessaloniki, Thessaloníki, Greece, 14Dalhousie University, Halifax, NS, Canada, 15Children’s Hospital of Pittsburgh, Pittsburgh, PA, 16National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 17University of Arkansas for Medical Sciences, Little Rock, AR, 18Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, 19Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 20Bristol-Myers Squibb Company, Princeton, NJ, 21PRINTO, Istituto Giannina Gaslini, Genova, Italy, 22Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
  • Abstract Number: 0734 • ACR Convergence 2020

    Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

    Jordan Jones1, Chelsey Smith2, Daniel J Lovell3 and Mara Becker4, 1Children's Mercy Kansas City, Kansas City, MO, 2Children's Mercy Kansas City, Holden, MO, 3PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Duke University School of Medicine, Durham, NC

    Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…
  • Abstract Number: 1683 • ACR Convergence 2020

    Ready or Not? Measuring Readiness for Transition to Adult Care in Adolescents with JIA & jSLE

    Jeanine McColl1, Teresa Semalulu1, Arzoo Alam2, Steffy Thomas2, Julie Herrington3, Jan Willem Gorter2, Tania Cellucci2, Stephanie Garner2, Liane Heale2, Mark Matsos2, Karen Beattie1 and Michelle Batthish4, 1McMaster University, Hamilton, ON, Canada, 2McMaster University, Hamilton, Canada, 3The Canadian Arthritis Society, Hamilton, Canada, 4McMaster Children's Hospital, Hamilton, ON, Canada

    Background/Purpose: Transitioning from pediatric to adult care represents a particularly vulnerable period among patients with JIA and jSLE. The shift to adult care is often…
  • Abstract Number: 0715 • ACR Convergence 2020

    JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept

    Nicolino Ruperto1, Hermine I Brunner2, Alberto Berman3, Francisco Ávila-Zapata4, Gerd Horneff5, Maria Alessio6, Mara Becker7, Alexandre Belot8, Ruben Burgos-Vargas9, Alina Boteanu10, Claudia Goldenstein-Schainberg11, Iloite Scheibel12, Maria Teresa Terreri13, Lawrence Zemel14, Robert Wong15, Margarita Askelson15, Marleen Nys16, Alberto Martini17 and Daniel J Lovell2, 1Istituto Giannina Gaslini, Genova, Italy, 2PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Universidad Nacional de Tucumán and Centro Médico Privado de Reumatología, Tucumán, Argentina, 4Star Medica Hospital, Merida, Yucatan, Mexico, 5Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 6Università di Napoli Federico II, Naples, Italy, 7Duke University School of Medicine, Durham, NC, 8Centre Hospitalier Universitaire de Lyon, Lyon, France, 9Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, 10Hospital Universitario Ramón y Cajal, Madrid, Spain, 11University of São Paulo, São Paulo, Brazil, 12Hospital Criança Conceição, Porto Alegre, Brazil, 13Federal University of São Paulo, São Paulo, Brazil, 14Connecticut Children’s Medical Center, Hartford, CT, 15Bristol-Myers Squibb Company, Princeton, NJ, 16Bristol-Myers Squibb Company, Braine-L’Alleud, Belgium, 17PRINTO, Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Effectiveness of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label Phase III international study (NCT01844518). Here we assess…
  • Abstract Number: 1148 • ACR Convergence 2020

    The SHARE Recommendations on Diagnosis and Treatment of Systemic JIA

    Arjen Leek1, Jordi Anton2, Tadej Avcin3, Fabrizio De Benedetti4, Victor Boom1, Claudia Bracaglia5, Paul Brogan6, Tamas Constantin7, Alessandro Consolaro8, Pavla Dolezalova9, Despina Eleftheriou10, Helen Foster11, Claas Hinze12, Isabelle Koné-Paut13, Kirsten Minden14, Francesca Minoia15, Pierre Quartier16, Angelo Ravelli8, Nicolino Ruperto17, Joost Swart18, Yosef Uziel19, Helmut Wittkowski20, Carine Wouters21, Mojca Zajc Avramovitz22, Nico Wulffraat18 and Sebastiaan Vastert1, 1University Medical Center Utrecht, Utrecht, Netherlands, 2Sant Joan de Déu Hospital, Madrid, Spain, 3Ljubljana University Medical Centre, Ljubljana, Slovenia, 4Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 5Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 6UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 7Semmelweiss University Hospital, Budapest, Hungary, 8Università degli Studi di Genova, Genoa, Italy, 9University Hospital Prague, Prague, Czech Republic, 10UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, 11Newcastle University, Newcastle upon Tyne, United Kingdom, 12University Hospital M�nster, M�nster, Germany, 13Necker Hospital, Paris, France, 14Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 15Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, 16Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 17Istituto Giannina Gaslini, Genova, Italy, 18IRCCS Istituto Giannina Gaslini, PRINTO, Genoa, Italy, Genova, Italy, 19Meir Medical Center, Kfar Saba, Israel, 20University Hospital Muenster, Muenster, Germany, 21University Hospital Leuven, Leuven, Belgium, 22University Hospital Ljubljana, Ljubljana, Slovenia

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex auto-inflammatory disease with significant morbidity including fever, rash, serositis and articular problems. With the availability…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.